VCYT
Veracyte, Inc.$59.13+2.50 (+4.42%)Prev Close$56.62·MCap$4.55B·P/E52.48·Vol524.4K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
40
$22.29M
◆
Net Activity
Net Seller
$22.29M
●
Active Insiders
10
last 12 mo
Over the past 12 months, insider activity at Veracyte, Inc. (VCYT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 40 insider sales totaling $22.29M. The most recent insider transaction was by EASTHAM KARIN (director), who sold $197.2K worth of shares on Jun 22, 2026. Veracyte, Inc. operates in the Healthcare sector, within the Medical - Diagnostics & Research industry, with a market cap of $4.55B.
VCYT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | EASTHAM KARIN | director | Sell | 3,729 | $52.89 | $197.2K | 15,626 |
| Jun 4, 2026 | Stapley Marc | director, officer: Chief Executive Officer | Sell | 138,051 | $50.12 | $6.92M | 440,494 |
| Jun 4, 2026 | Chambers Rebecca | officer: Chief Financial Officer | Sell | 3,561 | $49.73 | $177.1K | 175,241 |
| Jun 4, 2026 | McGuire Annie | officer: EVP, General Counsel | Sell | 3,176 | $49.76 | $158.0K | 139,016 |
| Jun 4, 2026 | Leite John | officer: Global Chief Commercial Off | Sell | 13,975 | $50.07 | $699.7K | 132,305 |
| May 27, 2026 | Wygant Jonathan | officer: VP, Chief Accounting Officer | Sell | 24,000 | $45.40 | $1.09M | 45,434-35% |
| May 22, 2026 | EPSTEIN ROBERT S | director | Sell | 10,000 | $44.01 | $440.1K | 52,446 |
| May 8, 2026 | McGuire Annie | officer: SVP, General Counsel | Sell | 5,102 | $40.00 | $204.1K | 143,708 |
| Mar 6, 2026 | Chambers Rebecca | officer: Chief Financial Officer | Sell | 18,341 | $36.14 | $662.9K | 145,137 |
| Mar 6, 2026 | Leite John | officer: Chief Commercial Officer-CLIA | Sell | 5,260 | $35.19 | $185.1K | 107,580 |
| Mar 6, 2026 | McGuire Annie | officer: SVP, General Counsel | Sell | 6,658 | $35.55 | $236.7K | 96,370 |
| Mar 6, 2026 | Stapley Marc | director, officer: Chief Executive Officer | Sell | 45,523 | $35.97 | $1.64M | 383,833 |
| Dec 16, 2025 | McGuire Annie | SVP, General Counsel | Sell | 10,739 | $43.13 | $463.2K | 0 |
| Dec 5, 2025 | EASTHAM KARIN | Director | Sell | 20,000 | $45.45 | $908.9K | 0 |
| Dec 2, 2025 | Chambers Rebecca | Chief Financial Officer | Sell | 16,662 | $46.70 | $778.2K | 0 |
| Dec 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $46.16 | $136.4K | 0 |
| Dec 2, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 4,178 | $46.57 | $194.6K | 0 |
| Dec 2, 2025 | McGuire Annie | SVP, General Counsel | Sell | 4,474 | $46.52 | $208.1K | 0 |
| Dec 2, 2025 | Stapley Marc | Chief Executive Officer | Sell | 15,582 | $46.62 | $726.4K | 0 |
| Dec 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,325 | $46.16 | $61.2K | 0 |
| Nov 25, 2025 | JONES EVAN/ FA | Director | Sell | 1,106 | $50.25 | $55.6K | 0 |
| Nov 25, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,808 | $50.00 | $140.4K | 0 |
| Nov 20, 2025 | Holstein Jens | Director | Sell | 10,000 | $42.36 | $423.6K | 0 |
| Nov 7, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 10,920 | $41.20 | $449.9K | 0 |
| Nov 5, 2025 | Chambers Rebecca | Chief Financial Officer | Sell | 7,000 | $41.00 | $287.0K | 0 |
| Nov 5, 2025 | EASTHAM KARIN | Director | Sell | 9,674 | $40.02 | $387.2K | 0 |
| Nov 5, 2025 | JONES EVAN/ FA | Director | Sell | 43,196 | $45.06 | $1.95M | 0 |
| Nov 5, 2025 | McGuire Annie | SVP, General Counsel | Sell | 6,466 | $40.00 | $258.6K | 0 |
| Oct 6, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 8,349 | $36.02 | $300.7K | 0 |
| Oct 1, 2025 | EPSTEIN ROBERT S | Director | Sell | 21,473 | $35.08 | $753.2K | 0 |
| Oct 1, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,539 | $35.00 | $88.9K | 0 |
| Oct 1, 2025 | McGuire Annie | SVP, General Counsel | Sell | 2,160 | $35.00 | $75.6K | 0 |
| Sep 19, 2025 | McGuire Annie | SVP, General Counsel | Sell | 2,283 | $33.69 | $76.9K | 0 |
| Sep 4, 2025 | Stapley Marc | Chief Executive Officer | Sell | 7,667 | $30.41 | $233.1K | 0 |
| Sep 2, 2025 | Chambers Rebecca | Chief Financial Officer | Sell | 5,371 | $30.11 | $161.7K | 0 |
| Sep 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $30.11 | $89.0K | 0 |
| Sep 2, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,902 | $30.11 | $87.4K | 0 |
| Sep 2, 2025 | McGuire Annie | SVP, General Counsel | Sell | 3,507 | $30.11 | $105.6K | 0 |
| Sep 2, 2025 | Stapley Marc | Chief Executive Officer | Sell | 7,914 | $30.11 | $238.3K | 0 |
| Sep 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,648 | $30.11 | $49.6K | 0 |
| Jun 13, 2025 | Bhanji Muna | Director | Sell | 4,589 | $26.67 | $122.4K | 0 |
| Jun 13, 2025 | EASTHAM KARIN | Director | Sell | 4,590 | $26.66 | $122.4K | 0 |
| Jun 4, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,809 | $27.20 | $76.4K | 0 |
| Jun 2, 2025 | Chambers Rebecca | Chief Financial Officer | Sell | 5,370 | $26.74 | $143.6K | 0 |
| Jun 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $26.74 | $79.0K | 0 |
| Jun 2, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,900 | $26.74 | $77.5K | 0 |
| Jun 2, 2025 | McGuire Annie | SVP, General Counsel | Sell | 3,505 | $26.74 | $93.7K | 0 |
| Jun 2, 2025 | Stapley Marc | Chief Executive Officer | Sell | 9,399 | $26.74 | $251.3K | 0 |
| Jun 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,848 | $26.74 | $49.4K | 0 |
| Mar 6, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 7,411 | $31.66 | $234.6K | 0 |
Showing 1–50 of 122
1 / 3
VCYT Insider Buying Activity
The following table shows recent insider purchases of Veracyte, Inc. (VCYT) stock reported via SEC Form 4 filings.
No insider buying activity found for VCYT in the last 12 months.
VCYT Insider Selling Activity
The following table shows recent insider sales of Veracyte, Inc. (VCYT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | EASTHAM KARIN | director | Sell | 3,729 | $52.89 | $197.2K | 15,626 |
| Jun 4, 2026 | Stapley Marc | director, officer: Chief Executive Officer | Sell | 138,051 | $50.12 | $6.92M | 440,494 |
| Jun 4, 2026 | Chambers Rebecca | officer: Chief Financial Officer | Sell | 3,561 | $49.73 | $177.1K | 175,241 |
| Jun 4, 2026 | McGuire Annie | officer: EVP, General Counsel | Sell | 3,176 | $49.76 | $158.0K | 139,016 |
| Jun 4, 2026 | Leite John | officer: Global Chief Commercial Off | Sell | 13,975 | $50.07 | $699.7K | 132,305 |
| May 27, 2026 | Wygant Jonathan | officer: VP, Chief Accounting Officer | Sell | 24,000 | $45.40 | $1.09M | 45,434-35% |
| May 22, 2026 | EPSTEIN ROBERT S | director | Sell | 10,000 | $44.01 | $440.1K | 52,446 |
| May 8, 2026 | McGuire Annie | officer: SVP, General Counsel | Sell | 5,102 | $40.00 | $204.1K | 143,708 |
| Mar 6, 2026 | Chambers Rebecca | officer: Chief Financial Officer | Sell | 18,341 | $36.14 | $662.9K | 145,137 |
| Mar 6, 2026 | Leite John | officer: Chief Commercial Officer-CLIA | Sell | 5,260 | $35.19 | $185.1K | 107,580 |
| Mar 6, 2026 | McGuire Annie | officer: SVP, General Counsel | Sell | 6,658 | $35.55 | $236.7K | 96,370 |
| Mar 6, 2026 | Stapley Marc | director, officer: Chief Executive Officer | Sell | 45,523 | $35.97 | $1.64M | 383,833 |
| Dec 16, 2025 | McGuire Annie | SVP, General Counsel | Sell | 10,739 | $43.13 | $463.2K | 0 |
| Dec 5, 2025 | EASTHAM KARIN | Director | Sell | 20,000 | $45.45 | $908.9K | 0 |
| Dec 2, 2025 | Chambers Rebecca | Chief Financial Officer | Sell | 16,662 | $46.70 | $778.2K | 0 |
| Dec 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $46.16 | $136.4K | 0 |
| Dec 2, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 4,178 | $46.57 | $194.6K | 0 |
| Dec 2, 2025 | McGuire Annie | SVP, General Counsel | Sell | 4,474 | $46.52 | $208.1K | 0 |
| Dec 2, 2025 | Stapley Marc | Chief Executive Officer | Sell | 15,582 | $46.62 | $726.4K | 0 |
| Dec 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,325 | $46.16 | $61.2K | 0 |
| Nov 25, 2025 | JONES EVAN/ FA | Director | Sell | 1,106 | $50.25 | $55.6K | 0 |
| Nov 25, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,808 | $50.00 | $140.4K | 0 |
| Nov 20, 2025 | Holstein Jens | Director | Sell | 10,000 | $42.36 | $423.6K | 0 |
| Nov 7, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 10,920 | $41.20 | $449.9K | 0 |
| Nov 5, 2025 | Chambers Rebecca | Chief Financial Officer | Sell | 7,000 | $41.00 | $287.0K | 0 |
| Nov 5, 2025 | EASTHAM KARIN | Director | Sell | 9,674 | $40.02 | $387.2K | 0 |
| Nov 5, 2025 | JONES EVAN/ FA | Director | Sell | 43,196 | $45.06 | $1.95M | 0 |
| Nov 5, 2025 | McGuire Annie | SVP, General Counsel | Sell | 6,466 | $40.00 | $258.6K | 0 |
| Oct 6, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 8,349 | $36.02 | $300.7K | 0 |
| Oct 1, 2025 | EPSTEIN ROBERT S | Director | Sell | 21,473 | $35.08 | $753.2K | 0 |
| Oct 1, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,539 | $35.00 | $88.9K | 0 |
| Oct 1, 2025 | McGuire Annie | SVP, General Counsel | Sell | 2,160 | $35.00 | $75.6K | 0 |
| Sep 19, 2025 | McGuire Annie | SVP, General Counsel | Sell | 2,283 | $33.69 | $76.9K | 0 |
| Sep 4, 2025 | Stapley Marc | Chief Executive Officer | Sell | 7,667 | $30.41 | $233.1K | 0 |
| Sep 2, 2025 | Chambers Rebecca | Chief Financial Officer | Sell | 5,371 | $30.11 | $161.7K | 0 |
| Sep 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $30.11 | $89.0K | 0 |
| Sep 2, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,902 | $30.11 | $87.4K | 0 |
| Sep 2, 2025 | McGuire Annie | SVP, General Counsel | Sell | 3,507 | $30.11 | $105.6K | 0 |
| Sep 2, 2025 | Stapley Marc | Chief Executive Officer | Sell | 7,914 | $30.11 | $238.3K | 0 |
| Sep 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,648 | $30.11 | $49.6K | 0 |
| Jun 13, 2025 | Bhanji Muna | Director | Sell | 4,589 | $26.67 | $122.4K | 0 |
| Jun 13, 2025 | EASTHAM KARIN | Director | Sell | 4,590 | $26.66 | $122.4K | 0 |
| Jun 4, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,809 | $27.20 | $76.4K | 0 |
| Jun 2, 2025 | Chambers Rebecca | Chief Financial Officer | Sell | 5,370 | $26.74 | $143.6K | 0 |
| Jun 2, 2025 | Febbo Phillip G. | Chief Scientific & Med Officer | Sell | 2,955 | $26.74 | $79.0K | 0 |
| Jun 2, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 2,900 | $26.74 | $77.5K | 0 |
| Jun 2, 2025 | McGuire Annie | SVP, General Counsel | Sell | 3,505 | $26.74 | $93.7K | 0 |
| Jun 2, 2025 | Stapley Marc | Chief Executive Officer | Sell | 9,399 | $26.74 | $251.3K | 0 |
| Jun 2, 2025 | Wygant Jonathan | VP, Chief Accounting Officer | Sell | 1,848 | $26.74 | $49.4K | 0 |
| Mar 6, 2025 | Leite John | Chief Commercial Officer-CLIA | Sell | 7,411 | $31.66 | $234.6K | 0 |
VCYT Insiders
Stapley Marc
director, officer: Chief Executive Officer
Bought $980.1KSold $13.87M
10 tradesLast: Jun 4, 2026
Similar Stocks to VCYT
TMO
Thermo Fisher Scientific Inc.
$536.62+0.50%
$189.57B
DHR
Danaher Corporation
$200.73+0.88%
$135.02B
NTRA
Natera, Inc.
$277.82+1.92%
$39.30B
A
Agilent Technologies, Inc.
$135.38+0.10%
$36.45B
ILMN
Illumina, Inc.
$186.25-2.52%
$28.78B
DGX
Quest Diagnostics Incorporated
$202.84-1.44%
$22.96B
LH
Labcorp Holdings Inc.
$273.00-0.96%
$22.70B
GH
Guardant Health, Inc.
$164.20+2.69%
$21.22B